ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 58

In Rheumatoid Arthritis (RA) Decreases in Conventional Dendritic Cell Lineages Are Associated with Adverse Measures of Myocardial Function and Expansions of Anomalous HLA-DR+ Myeloid Subsets

Christian Geier1, Jon Giles 2, Gilad Gibor 3, Joan Bathon 2 and Robert Winchester 3, 1Columbia University, New York, NY, 2Division of Rheumatology, Columbia University, New York, NY, 3Columbia University, New York

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Cardiovascular disease, Dendritic cells, flow cytometry and 18FDG PET/CT scan, Rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: RA – Etiology & Pathogenesis Poster I

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Dendritic cells (DC) are specialized antigen-presenting cells (APC) that have a central role in the initiation of immune responses. However, prior studies showed numeric decreases of myeloid (mDC) and plasmacytoid (pDC) DC in RA. This apparent contradiction led us to hypothesize that depletion of these ‘canonical’ DC is only one manifestation of a more fundamental alteration in this important immunoregulatory compartment in RA and that the overall non-lymphoid APC population (CD3–CD19–HLA-DR+) does not decrease due to the appearance of anomalous APC phenotypes. We further hypothesized that alterations in DC subsets are associated with clinical aspects of RA including those driving RA-associated cardiovascular disease.

Methods: RA patients enrolled in a cohort study and healthy donors underwent immunophenotyping to define known DC subsets, including CD1c+ mDC, CD141+ mDC and CD303+ pDC in peripheral blood mononuclear cells (PMBCs). We correlated DC subset features with disease characteristics and cardiac function. To screen for non-lymphoid cells with putative APC potential not conforming to conventional DC paradigms we defined ‘candidate nonlymphoid APC’ (DR+CD3–CD19–CD56–) as a DC superset. We used t-Distributed Stochastic Neighbor Embedding (t-SNE) to categorize the entirety of non-lymphoid APC candidate cells and identify possible novel RA APC subsets.

Results: Circulating CD1c+ frequencies were, as expected, remarkably decreased in RA (mean 1.0% of PBMCs vs controls 2.6%; p=0.009). Mean CD141+ frequencies were 0.1% (RA) vs 0.2%; p=0.019. CD303+ pDC frequencies did not differ (p=0.285). HLA-DR intensity in both myeloid subsets was significantly lower in RA whereas CCR2 intensity was higher in CD1c+ DC. In RA, a lower CD1c+ frequency was associated with lower cardiac index (corr.=-0.54, p=0.008) and CCR2 expression of CD1c+ DC was associated with lower Ejection Fraction (EF) (corr.=-0.70, p=0.001). Interestingly, despite the decrease in canonical DC; the overall frequencies of ‘candidate non-lymphoid APC’ did not differ (Table 1) suggesting that the declines of canonical DC were compensated for by increases in other populations of this DR+ DC superset. t-SNE analysis of healthy controls allowed clear categorization with distinct clusters of APC subsets as well as a homogenous cluster of CD14–CD16–CD11c+(Figure 2; orange circle). RA t-SNE showed a decrease of canonical DC subsets (yellow ellipses) and the appearance of five clusters with some DC features that did not fit accepted definitions (Figure 2a-e)

Conclusion: We found extensive alterations in the DC compartment in RA, including a significant decrease in the major CD1c+ subset and the emergence of anomalous HLA-DR+ non-lymphoid cells with antigen-presenting potential that are candidate DC subsets. The novel subsets included one resembling CD14+ monocyte-derived DC, a subset of which also expressed CD1c in addition to plasmacytoid markers; CD303 and CD123. The remaining populations were distinguished by combinations of CCR2, CD11c, CD123 and CD172a (SIRPα). The association of adverse measures of cardiac function with changes of the DC compartment, including decreases of CD1c+ mDC, emphasize their potential clinical significance.


Table 1 – Enumeration and expression of DR and CCR2 Expression in DC subsets in RA

Table 1 – Enumeration and expression of HLA-DR and CCR2 in DC subsets of Rheumatoid Arthritis patients compared with controls


t-SNE healthy control

Figure 1 – t-SNE representation of non-lymphoid HLA-DR+ cells with APC potential of a healthy donor.
Red circles: monocyte populations. Yellow: DC populations. A small homogenous population of CD14-CD16-CD11c+ cells without DC characteristics is shown in orange.

Classical monocytes: CD14+CD16+
Intermediate monocytes: CD14+CD16+
Nonclassical monocytes: CD14-CD16+

CD1c+ cDC: CD11c+CD1c+
CD141+ cDC: CD11c+ CD141+
pDC: 11c-CD303+


t-SNE RA

Figure 3 – t-SNE representation of non-lymphoid HLA-DR+ cells with APC potential of an RA patient.
Red circles: monocyte populations. Yellow: DC populations. Orange: DR+ cells which do not conform to standard DC paradigms but express partial DC markers.

a- CD14+ CD1c+ CD141+ CD172a+ CD123+- b- CD14-CD16- 11c+ c- CD14-CD16- CD172a+ d- CD123+ e- CD14- CD16- CD45RA+-

Classical monocytes: CD14+CD16+
Intermediate monocytes: CD14+CD16+
Nonclassical monocytes: CD14-CD16+

CD1c+ cDC: CD11c+CD1c+
CD141+ cDC: CD11c+ CD141+
pDC: 11c-CD303+


Disclosure: C. Geier, None; J. Giles, Eli Lilly & Company, 5, Pfizer Inc, 2; G. Gibor, None; J. Bathon, None; R. Winchester, None.

To cite this abstract in AMA style:

Geier C, Giles J, Gibor G, Bathon J, Winchester R. In Rheumatoid Arthritis (RA) Decreases in Conventional Dendritic Cell Lineages Are Associated with Adverse Measures of Myocardial Function and Expansions of Anomalous HLA-DR+ Myeloid Subsets [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/in-rheumatoid-arthritis-ra-decreases-in-conventional-dendritic-cell-lineages-are-associated-with-adverse-measures-of-myocardial-function-and-expansions-of-anomalous-hla-dr-myeloid-subsets/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/in-rheumatoid-arthritis-ra-decreases-in-conventional-dendritic-cell-lineages-are-associated-with-adverse-measures-of-myocardial-function-and-expansions-of-anomalous-hla-dr-myeloid-subsets/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology